173 related articles for article (PubMed ID: 35806460)
21. Histology-driven chemotherapy of soft-tissue sarcoma.
Eriksson M
Ann Oncol; 2010 Oct; 21 Suppl 7():vii270-6. PubMed ID: 20943627
[TBL] [Abstract][Full Text] [Related]
22. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
24. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
[TBL] [Abstract][Full Text] [Related]
25. Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin.
Pantazopoulou A; Galmarini CM; Peñalva MA
Sci Rep; 2018 Jun; 8(1):8616. PubMed ID: 29872155
[TBL] [Abstract][Full Text] [Related]
26. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
[TBL] [Abstract][Full Text] [Related]
27. In brief: Two Drugs for soft-tissue sarcoma.
Med Lett Drugs Ther; 2016 May; 58(1494):e62. PubMed ID: 27148925
[No Abstract] [Full Text] [Related]
28. Interdimeric Curvature in Tubulin-Tubulin Complexes Delineates the Microtubule-Destabilizing Properties of Plocabulin.
Navarrete KR; Jiménez VA
J Chem Inf Model; 2020 Aug; 60(8):4076-4084. PubMed ID: 32687349
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model.
Frazier JP; Beirne E; Ditzler SH; Tretyak I; Casalini JR; Thirstrup DJ; Knoblaugh S; Ward JG; Tripp CD; Klinghoffer RA
Vet Comp Oncol; 2017 Sep; 15(3):754-763. PubMed ID: 26991424
[TBL] [Abstract][Full Text] [Related]
30. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
[TBL] [Abstract][Full Text] [Related]
31. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
[TBL] [Abstract][Full Text] [Related]
32. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
Schliemann C; Hemmerle T; Berdel AF; Angenendt L; Kerkhoff A; Hering JP; Heindel W; Hartmann W; Wardelmann E; Chawla SP; de Braud F; Lenz G; Neri D; Kessler T; Berdel WE
Eur J Cancer; 2021 Jun; 150():143-154. PubMed ID: 33901793
[TBL] [Abstract][Full Text] [Related]
33. Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.
Tian Z; Dong S; Yang Y; Gao S; Yang Y; Yang J; Zhang P; Wang X; Yao W
BMC Cancer; 2022 Jan; 22(1):56. PubMed ID: 35022029
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
35. Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model.
Hiroshima Y; Zhang Y; Zhang N; Uehara F; Maawy A; Murakami T; Mii S; Yamamoto M; Miwa S; Yano S; Momiyama M; Mori R; Matsuyama R; Chishima T; Tanaka K; Ichikawa Y; Bouvet M; Endo I; Hoffman RM
Anticancer Res; 2015 Feb; 35(2):697-701. PubMed ID: 25667448
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
[TBL] [Abstract][Full Text] [Related]
37. Establishing efficient xenograft models with intrinsic vascularisation for growing primary human low-grade sarcomas.
Tilkorn D; Daigeler A; Stricker I; Schaffran A; Schmitz I; Steinstraesser L; Hauser J; Ring A; Steinau HU; Al-Benna S
Anticancer Res; 2011 Dec; 31(12):4061-6. PubMed ID: 22199262
[TBL] [Abstract][Full Text] [Related]
38. Current and advancing systemic treatment options for soft tissue sarcomas.
Harris SJ; Benson C; Jones RL
Expert Opin Pharmacother; 2015; 16(13):2023-37. PubMed ID: 26255951
[TBL] [Abstract][Full Text] [Related]
39. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
40. PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.
Martínez-Díez M; Guillén-Navarro MJ; Pera B; Bouchet BP; Martínez-Leal JF; Barasoain I; Cuevas C; Andreu JM; García-Fernández LF; Díaz JF; Avilés P; Galmarini CM
Biochem Pharmacol; 2014 Apr; 88(3):291-302. PubMed ID: 24486569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
